What you'll learn

  • Describe current understanding of epidemiology, risk factors, pathobiology, societal costs, clinical differences, gaps in knowledge, and challenges in distinguishing and managing the spectra of normal cognitive aging, mild cognitive impairment (MCI), Alzheimer’s disease (AD) and other neurodegenerative dementias
  • Distinguish pre-clinical AD, MCI due to AD/prodromal AD and AD dementia phases
  • Summarize tiered diagnostic and management approaches, and future experimental therapeutics strategies under consideration for risk reduction, prevention diagnosis and treatment of the AD spectrum
  • Differentiate, based on neuropathology, affected neural systems, clinical criteria and biomarkers, AD and its atypical variants from other common dementias including Dementia with Lewy Bodies (DLB), Vascular Cognitive Impairment (VCI)/Vascular-Ischemic Dementia, Frontotemporal Degeneration (FTD), Parkinson’s disease with Dementia (PDD), Parkinson’s-Plus Syndromes and less common dementias
  • See the course registration page for additional learning objectives

Course description

This is an accredited, livestreamed course offered by Brigham and Women's Hospital and Massachusetts General Hospital. This course is targeted to Primary Care Physicians, Specialty Physicians, Nurses, Nurse Practitioners, Physician Assistants, and Psychologists.

Select the Take Course button to view additional information on the course registration page.

Contact ceprograms@hms.harvard.edu with questions.

*Register before August 15 to receive the discounted price.

Enroll now.
Learn More